{
  "id": "mhgap#risk_safety_e627fc2d",
  "content": "developmental and behavioural disorders in children\nburden of disease as measured in disability-adjusted\nand adolescents; dementia; alcohol use disorders;\nlife-years (DALYs) and 25.1% of all years lived with\ndrug use disorders; and self-harm/suicide and other\ndisability (1). The resources that have been provided\nsignificant emotional or medically unexplained\nto tackle the huge burden of MNS disorders are\ncomplaints (7). The priority conditions were selected as\ninsufficient, inequitably distributed and inefficiently\nthey represented a large burden in terms of mortality,\nused (2). The result is a large treatment gap, more\nmorbidity or disability; have high economic costs;\nthan 75% in many countries with low and lower\nand are often associated with violations of human\nmiddle incomes (1,3). The stigma and discrimination\nrights. Additionally, as part of the scaling-up strategy\nassociated with MNS conditions further exacerbates\nof mhGAP in countries, derivative products based on\nthe issues and creates additional barriers for people to\nmhGAP guidelines were developed.\nseek and access care (4).\nIn keeping with WHO’s practice of regularly monitoring\nTo reduce the treatment gap and to enhance the\nnew and emerging evidence, a new edition of the\ncapacity of countries to respond to the growing",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "high",
    "topics": [
      "risk_safety",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety developmental and behavioural disorders in children\nburden of disease as measured in disability-adjusted\nand adolescents; dementia; alcohol use disorders;\nlife-years (DALYs) and 25.1% of all years lived with\ndrug use disorders; and self-harm/suicide and other\ndisability (1). The resources that have been provided\nsignificant emotional or medically unexplained\nto tackle the huge burden of MNS disorders are\ncomplaints (7). The priority conditions were selected as\ninsufficient, inequitably distributed and inefficiently\nthey represented a large burden in terms of mortality,\nused (2). The result is a large treatment gap, more\nmorbidity or disability; have high economic costs;\nthan 75% in many countries with low and lower\nand are often associated with violations of human\nmiddle incomes (1,3). The stigma and discrimination\nrights. Additionally, as part of the scaling-up strategy\nassociated with MNS conditions further exacerbates\nof mhGAP in countries, derivative products based on\nthe issues and creates additional barriers for people to\nmhGAP guidelines were developed.\nseek and access care (4).\nIn keeping with WHO’s practice of regularly monitoring\nTo reduce the treatment gap and to enhance the\nnew and emerging evidence, a new edition of the\ncapacity of countries to respond to the growing Developmental and behavioural disorders in children\nburden of disease as measured in disability-adjusted\nand adolescents; dementia; alcohol use disorders;\nlife-years (dalys) and 25.1% of all years lived with\ndrug use dis..."
}